Logotipo del SMU

RMU

Uruguayan Medical Journal

ISSN: 1688-0390


Vol.12 - Nº 2 - Oct. 1996

Previous Art | Index | Next Art

Autologous bone marrow transplant (BMT) with bone marrow and peripheral blood progenitors

NESE M; PERDOMO S; PERDOMO A; GUILLERMO C; DÍAZ L; ISAURRALDE H; GRINBERG S; AGHAZARIAN M; VARANGOT M; MASI M; CAMEJO E
Rev Med Urug 1996; 12: 106-111
Full text (spanish) |  Full text (spanish) (New windows, pdf) | Abstract

Abstract

In May 1995 a protocol was set up of autologous bone marrow transplant (BMT) with bone marrow progenitors (BMCS) and peripherical blood (PSCS) stimulated by

growth factors. Its aim was to improve the results obtained with the sole use of bone marrow progenitors. The treatment involved 30 adult patients, 18 males and 12 females, 11 non Hodgkin?s lymphoma (NHL), 4 Hodgkin?s lymphoma (HL), 5 acute leukemia (AC), 1 multiple myeloma and 9 solid tumors. All of them were given G-CSF previous to BMCS harvesting and obtainment of PB. The mean of infunded mononuclear cells was 15,36 108/kg. The mean recovery of neutrophile granulocytes was 9,5 days and that of blood platelets 13,8. The mean replenishment with red cell and platelet concentrates was 2 and 1, respectively. The duration of febrile episodes, of antibiotic requirement and of mean hospitalization involved 2, 5,2 and 26 days. Mortality related to the transplant was O. With this technology it was possible to diminish the postinfusion aplasia, the mean of days and hospitalization, transfusion

requirements and infectious complications.